Kmt2D And Tp53 Mutations Predict Poor Pfs And Os In Mantle Cell Lymphoma Receiving High‐Dose Therapy And Asct: The Fondazione Italiana Linfomi (Fil) Mcl0208 Phase Iii Trial
AuthID
P-015-0TD
P-015-0TD